Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Current Deferred Revenue: 2014-2020

Historic Current Deferred Revenue for Aytu Biopharma (AYTU) over the last 4 years, with Dec 2020 value amounting to $475,680.

  • Aytu Biopharma's Current Deferred Revenue was N/A to $475,680 in Q4 2020 from the same period last year, while for Dec 2020 it was $475,680, marking a year-over-year change of. This contributed to the annual value of $339,336 for FY2020, which is N/A change from last year.
  • According to the latest figures from Q4 2020, Aytu Biopharma's Current Deferred Revenue is $475,680, which was up 104.53% from $232,576 recorded in Q3 2020.
  • Aytu Biopharma's 5-year Current Deferred Revenue high stood at $475,680 for Q4 2020, and its period low was $1,450 during Q2 2018.
  • For the 2-year period, Aytu Biopharma's Current Deferred Revenue averaged around $177,692, with its median value being $123,283 (2018).
  • In the last 5 years, Aytu Biopharma's Current Deferred Revenue soared by 397.00% in 2016 and then slumped by 98.43% in 2017.
  • Over the past 4 years, Aytu Biopharma's Current Deferred Revenue (Quarterly) stood at $426,000 in 2016, then tumbled by 98.43% to $4,787 in 2017, then skyrocketed by 192.25% to $13,990 in 2018, then reached $475,680 in 2020.
  • Its Current Deferred Revenue was $475,680 in Q4 2020, compared to $232,576 in Q3 2020 and $339,336 in Q2 2020.